Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 5/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31276198 | 1.00 | KMT2A (0.44) | KMT2ACA1CA2CA4MT-CO2 | |
| SCHEMBL8902053 | 1.00 | KMT2A (0.44) | KMT2ACA1CA2CA4MT-CO2 | |
| SCHEMBL22397285 | 0.97 | CA1 (0.42) | KMT2ACA1CA2CA4MT-CO2 | |
| SCHEMBL11955 | 0.97 | CA1 (0.42) | KMT2ACA1CA2CA4MT-CO2 | |
| SCHEMBL12333841 | 0.97 | CA1 (0.42) | KMT2ACA1CA2CA4MT-CO2 | |
| SCHEMBL895510 | 0.97 | CA1 (0.42) | KMT2ACA1CA2CA4MT-CO2 | |
| SCHEMBL120444 | 0.97 | CA1 (0.42) | KMT2ACA1CA2CA4MT-CO2 | |
| SCHEMBL3477839 | 0.95 | KMT2A (0.50) | KMT2ACA1CA2CA4MT-CO2 | |
| SCHEMBL3721835 | 0.95 | KMT2A (0.50) | KMT2ACA1CA2CA4MT-CO2 | |
| SCHEMBL3397908 | 0.95 | KMT2A (0.50) | KMT2ACA1CA2CA4MT-CO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290691-B2 | Organic el material-containing solution, method for forming organic el thin film, organic el device comprising organic el thin film, and method for manufacturing organic el display panel | IDEMITSU KOSAN CO., LTD. (JP) | 2016-03-22 | — | — | US | claimed |
| CN-117957230-A | RIP1 kinase inhibitors and uses thereof | 维泰瑞隆（北京）生物科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-2117061-B9 | ORGANIC EL MATERIAL-CONTAINING SOLUTION AND METHOD FOR FORMING ORGANIC EL THIN FILM | IDEMITSU KOSAN CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| EP-2117061-B1 | ORGANIC EL MATERIAL-CONTAINING SOLUTION AND METHOD FOR FORMING ORGANIC EL THIN FILM | IDEMITSU KOSAN CO (JP) | 2017-05-24 | — | — | EP | disclosed |
| EP-2487150-B1 | PROCESS FOR PRODUCING A LACTONE | KAO CORP (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-9290691-B2 | Organic el material-containing solution, method for forming organic el thin film, organic el device comprising organic el thin film, and method for manufacturing organic el display panel | IDEMITSU KOSAN CO., LTD. (JP) | 2016-03-22 | — | — | US | disclosed |
| US-20150065490-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| EP-2487150-A1 | PROCESS FOR PRODUCING 2-ALKYLCYCLOALKANONE | Kao Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20100117028-A1 | ORGANIC EL MATERIAL-CONTAINING SOLUTION, METHOD FOR FORMING ORGANIC EL THIIN FILM, ORGANIC EL DEVICE COMPRISING ORGANIC EL THIN FILM, AND METHOD FOR MANUFACTURING ORGANIC EL DISPLAY PANEL | IDEMITSU KOSAN CO., LTD. (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2117061-A1 | ORGANIC EL MATERIAL-CONTAINING SOLUTION, METHOD FOR FORMING ORGANIC EL THIN FILM, ORGANIC EL DEVICE COMPRISING ORGANIC EL THIN FILM, AND METHOD FOR MANUFACTURING ORGANIC EL DISPLAY PANEL | Idemitsu Kosan Co., Ltd. (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-1529038-B1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-10-07 | — | — | EP | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| CN-1301980-C | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2007-02-28 | — | — | CN | disclosed |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| CN-1701064-A | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2005-11-23 | — | — | CN | disclosed |
| EP-1529038-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | Novartis AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004016601-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | KMT2A 2661/4885CA1 3851/4885CA2 739/4885 |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | KMT2A 2661/4885CA1 3851/4885CA2 739/4885 |
| US-20150065490-A1 | ORGANIC COMPOUNDS | ADRB2, ADRA2C, ADRB1 | KMT2A 3108/4885CA1 1482/4885CA2 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.